Antibiotics

A paradigm shift is emerging when it comes to the clinical approach to prescribing antibiotics. One clinician weighs in on using this class of therapeutics more judiciously.

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.

This was the first study to compare clinical outcomes in carbapenemase-producing (CP-CRE) and non–carbapenemase-producing (nCP-CRE) infections.

The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) voted 12-0 in favor of recommending this antibiotic and sets up a PDUFA target action date of May 29.

With an FDA approval, it would be the first new class of oral antibiotics for uncomplicated urinary tract infections (uUTI) in over 20 years.

Several years after its FDA approval, this antibiotic continues to prove its efficacy in vitro across various pathogens related to these infections.

Alita Miller, PhD, senior vice president of research at Entasis Therapeutics, discusses positive trial data for Sulbactam-durlobactam (SUL-DUR) slated to be presented at ECCMID 2023.

Catch up with this week's 5 most-read infectious disease stories.

With limited amounts of antibacterials, prescribers are presented with optimal therapy challenges as well as difficulties in trying to achieve stewardship.

Reducing unnecessary antibiotic prescriptions for viral upper respiratory tract infections is crucial to stop the spread of antimicrobial resistance.

2 CDI recurrences occurred in this study, both in placebo recipients who were immunocompromised.

According to the CDC, the outbreak strain of carbapenem-resistant Pseudomonas aeruginosa with Verona integron-mediated metallo-β-lactamase and Guiana extended-spectrum-β-lactamase (VIM-GES-CRPA), has never been reported in the US prior to this outbreak.

Increased sales of these antibiotics during the COVID-19 pandemic raise concerns about the growing threat of antimicrobial resistance.

"Antibiotics can safely be withheld in most patients with viral respiratory infections,” these study authors wrote.

An intensive care physician offers some insights looking at fluoroquinolone-associated tendinopathy and using this social media platform to provide education and an open discussion around it.

This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.

A food for thought as an ambulatory antibiotic stewardship initiative.

Candida auris fungal infections increased 95% in 2021, and drug-resistant cases are continuing to spread across the US.

A study demonstrated patients were frequently prescribed broad-spectrum antibiotics when more narrowly tailored antibiotics were considered the optimal choice.

A third to a half of PPIs are overprescribed, potentially leading to an increased risk of the colonization with drug-resistant microorganisms.

This study analyzed concerns that a lack of time may lead primary care physicians to prescribe unnecessarily as a “quick fix.”

The congressional bill has been on Capitol Hill for over 2 years now, and the interested stakeholders are continuing their lobbying efforts to get it passed.

A single oral dose of azithromycin reduced the risk of maternal sepsis or death by 33% in women who delivered vaginally.

Antimicrobial stewardship programs can protect drugs listed on the WHO Watch List, but the benefits are also dependent on countries' income level.

An increase in extensively drug-resistant Shigella infections prompted the CDC to release a health advisory for this major cause of bacterial diarrhea.

"This case gives uncomfortable insight into a gap in early detection of infections in immunocompromised, high-risk patient populations. "

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.

Carbapenem-resistant Enterobacterales present considerable treatment challenges. Recent cumulative evidence supports preference for therapies.

Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.